Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Man oh man!!! We have arrived! It's all out in the open now after years of denial. Now the disciples job is to somehow normalize all this nonsense.
>>Of course the payments and revs are going to heavily favor Advent at this point. That is how the structure works.
...Be honest for once, disciples, what would Joan's latest article look like assuming she was sincere in her Specials rev projections?
LOL...BioHarm. You're awful. She already did it once with Cognate and now this Advent show. It's exhibitionism at its best! She thinks she's Warren Buffet but without share appreciation or shareholder love. Buffet didn't do cc's either. LOL
>>She found a way around this
How pissed would poor Joan Lappin be if she were alive today to see this?
I think we all know why.
So why'd Lappin project $100M in Specials revs by 2022?
So say it then... "Poly ICLC is not yet approved by any regulators."
>>But sometimes people make things up because they want to believe something. They get it in their head.
A lot of legacy shareholders were created off that article.
At least the moving will be easy. A few chairs and desks and good to go.
Advent.
In 2011 there was that article with LP saying they were two years away.
Smoke and Mirrors.
No evidence of anything.
It's research for researches sake without having to burden true investors with BP decisions.
>>BP does pay a large amount to the FDA in fees. But they pay even more, proportionately, to the MHRA,
It took many more years than normal.
-NWBIO will never data lock
According to their own website the trial is still ongoing. LOL. It took twenty years to run with still unknown reaction from regulators for changing the design to an external control.
-They will never finish the trial
Dragged out for years. Data isn't solid.
-They will never release results
I admit JAMA surprised me. Thought it'd be that Italian journal they reported in previously. The JAMA pub hasn't gone without controversy, however. Also JAMA notes only Bosch responsible for the data.
-They will never get published
They did but only after tiny MHRA umbilical cord was cut from EMA. And, management was rewarded handsomely for submittal but not approval. We'll see in the fall.
-They will never apply for approvals
I ask you the simplest question to define "Lots" from your initial statement but you could not do it.
You're in total denial. I'm going to have to ignore you. Sorry.
Yep, that's what I thought. It's too embarrassing to think about.
LOL. One trial redo or required confirmatory and you've got a half dozen treatments for GBM in the race. And, at the pace this crew moves they'll be overtaken - Already being overtaken with so much time wasted.
>>pretend like they are a threat to DC VAX.
That would explain a lot.
>>I myself participated in over 30 clinical trials. You actually get compensated for them.
Tons of compelling free trials in progress. Unfortunately those trials won't accept patients if they've had some previous treatment like L.
You're ignoring the Nature, JAMA, and other articles / studies I've posted. Good work.
...IF a friend or loved one was ever diagnosed with GBM today, I'd likely tell them to radically change their diet, have GKRS while getting themselves into a mRNA, T cell or SurvaxM trial, and do whatever possible to avoid any heavy doses of chemo or avoid it all together.
If I ever see good data and real world OS evidence of combo L - Poly, then perhaps I'd recommend that too. But no chemo.
What for the crab legs? If I do tune in I'll hear what's relevant without needing to look in their eyes to find the truth. Eye rolls. Otherwise the ASM is just about the disciples claiming here to have a side conversation with the two lawyers.
No comment, of course.
Define "Lots".
That's because it's like LL said about not being able to patent the patients own tumor, only the process. Get it yet?
That's a musician.
"King Collage"
LOL. That coming from boiler boy himself, KIPK!!!
>>just because of your hatefull demeaner.
Have to agree. For the patients the allure of a therapy without grueling side effects is just too great to see the data for what it is. Perhaps if there was some identifiable subset where survival was greater.
Imagine this dope not even once mentioning concern for common shareholders piece of the ever shrinking pie.
Add to it that the SOC for GBM is almost certainly closer to 10% than 5% these days.
I really do hope AF or someone makes a documentary.
Your "Larger picture" dot connecting doesn't include poor retail shareholders...Never did. Watch and learn.
All this totally wacky time consuming nonsense but you can't simply email IR to confirm Les was accurate for the fall?
What makes no sense is a bunch of posters here claiming to be investors who have no issues with their agoraphobic CEO-CFO-Chairman, even as she sets up her own private CDMO company and puts it right in the middle of operations. That's just beyond anything I've ever seen -Both the boldness displayed by management and the timidness displayed by retail common.
Perhaps MHRA will consider running a PIP trial in combo as a confirmatory.
There seems to be some evidence it also works on its own.
>>and understood to be basically an adjuvant compound.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356196/
What softball questions are the disciples lining up for the ASM that won't even be answered?
Correct. But BioHarm needs everyone to think it is approved.
>>The FDA (the U.S. Food and Drug Administration) has not approved personalized neoantigen
peptides, Hiltonol® or Montanide® a as a treatment for any disease.
>>The FDA (the U.S. Food and Drug Administration) has not approved personalized neoantigen
peptides, Hiltonol® or Montanide® a as a treatment for any disease. It is an investigational
drug being developed for use in the treatment of metastatic melanoma.
The FDA has approved Nivolumab (Opdivo®) and Ipilimumab (Yervoy™) as a treatment option for
this disease.
The FDA has approved Ipilimumab administered intravenously as a treatment option for this
disease.
The FDA has not approved Ipilimumab administered subcutaneously (under the skin) as a
treatment for any disease.
https://www.mycancergenome.org/content/clinical_trials/NCT03929029/
>>The drug was also under development for the treatment of brain tumor, anaplastic astrocytoma, anaplastic oligoastrocytoma, oligodendroglioma, glioblastoma multiforme, poxviridae infections, west nile virus infections, japanese encephalitis, dengue fever, yellow fever, st louis encephalitis, murray valley, orthopox virus infections, banzai viruses, smallpox, severe acute respiratory syndrome (SARS), acute myeloid leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia (CMML) and influenza.
The company’s pipeline products include hiltonol plus dendritic cell vaccine and hiltonol (Poly-ICLC) plus temodar.
https://www.pharmaceutical-technology.com/data-insights/poly-iclc-oncovir-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/?cf-view
Says nothing really. No survival stats or testimonials?
>>They state a 70% response rate, which is a bit ambiguous.